Cathie Wood, Ark Investment’s chief executive, has said that the "most underappreciated application of AI" is health care.

BofA raised the firm’s price target on Tempus AI (TEM) to $60 from $54 and keeps a Neutral rating on the shares after the company reported Q4 ...

Skyrocketing 108% since the start of 2025, Tempus AI (NASDAQ: TEM), a company applying AI solutions to healthcare, has seen ...

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

DeepSeek is a stark reminder about the importance of strategic durability, and not just growth or growth potential, to a ...

Cathie Wood and Ark Invest seized the opportunity on Tuesday to buy the dip on Tempus AI (NASDAQ:TEM) as the stock took a 15% ...

Key Takeaways Tempus AI's fourth-quarter results missed estimates as its costs increased.The medical technology firm's ...

Tempus AI (NASDAQ: TEM) rocketed from about 44% higher. All on news it just acquired Ambry Genetics, a well-known leader in ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on ...

Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was up 12.7% on Wednesday after Needham & Company LLC raised their price target on the stock from $56.00 to $70.00. Needham & Company LLC currently has a ...

Despite optimistic news from the CEO yesterday afternoon, the company's shares fell overnight and a major investment house ...

Tempus AI's slowing growth, cash flow issues, and net debt raise doubts about its sustainability. Explore key concerns and ...